Softwr

Healthcare · head to head

Lunit vs Signant Health

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
Signant Health logo

Signant Health

Healthcare

eCOA-first clinical trial platform that has grown outward into EDC, eConsent and televisits

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; Signant Health no pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, Signant Health covers eCOA and ePRO.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and Signant Health actually diverge.

Attributes where Lunit and Signant Health differ
AttributeLunitSignant Health
PlatformsWebWeb, iOS, Android

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in Signant Health

  • eCOA and ePRO
  • Unified platform
  • eConsent
  • Randomisation and supplies
  • TeleVisits
  • Rater training
  • Data surveillance
  • Instrument library

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Signant Health
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Signant Health
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Signant Health
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Signant Health

Signant Health

  • A central nervous system or psychiatry trial where the primary endpoint is a rated scale and rater consistency decides the readoutnot Lunit
  • A global study needing an outcome instrument translated and linguistically validated across a dozen languagesnot Lunit
  • A decentralised or hybrid protocol combining televisits, eConsent and at-home patient reported outcomesnot Lunit
  • A sponsor consolidating separate eCOA, eConsent and randomisation vendors onto one platform to cut reconciliation worknot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Signant Health

  • No pricing is published, and the software licence is a minority of the real bill once instrument licensing, translations, device provisioning and services are added, so early budget estimates are routinely too low.
  • Linguistic validation is charged per instrument per language and is on the critical path to first patient in, so adding a country late in start-up produces both a cost and a schedule hit.
  • Provisioned participant devices bring logistics, replacement, shipping and cellular connectivity obligations that persist for the life of the trial and are frequently underestimated.
  • The EDC component is newer than the eCOA heritage, so sponsors with complex data management requirements often keep an incumbent EDC and lose the single-database benefit that justifies the platform.
  • It is priced and scoped for sponsor-grade trials, which makes it a poor fit for investigator-initiated or academic studies that need outcome collection without the services layer.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Signant Health

On request
  • SmartSignals Unified Platform$undefined/year
    • Priced per study through a sales process
    • Modules selected per protocol: EDC, eCOA, randomisation, eConsent, TeleVisits
    • Instrument licensing paid to scale owners on top of platform cost

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose Signant Health if

  • You need ecoa and epro.
  • You work on Web, iOS, Android.
  • You also want unified platform.
Signant Health review

Questions people ask

Is Lunit or Signant Health better?
Neither clearly leads. Lunit starts at On request and Signant Health at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or Signant Health?
Lunit starts at On request and Signant Health at On request.
Does Lunit or Signant Health run on more platforms?
Lunit runs on Web. Signant Health runs on Web, iOS, Android.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what Signant Health is typically brought in for.
What can Lunit do that Signant Health cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. Signant Health covers eCOA and ePRO, Unified platform, eConsent, Randomisation and supplies.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Signant Health: What is Signant best at?

Electronic clinical outcome assessment, particularly rated scales in central nervous system and psychiatry trials, together with rater training and endpoint quality services.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Signant Health: Is pricing published?

No. Everything is quoted per study, and instrument licences, translations and devices sit on top of the platform cost.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Signant Health: Can I use it only for eCOA?

Yes. The modules are selected per protocol, and many sponsors take eCOA and eConsent while keeping an existing EDC.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Signant Health: What drives the timeline?

Translation and linguistic validation of outcome instruments, which is per language per instrument and sits on the critical path to study start.

Share

Related pages

More on Lunit

More on Signant Health

Keep looking

Other head to heads